

Lizza E L Hendriks

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4081466/lizza-e-l-hendriks-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96
papers

2,128
citations

24
h-index

43
g-index

119
ext. papers

3,091
ext. citations

5.5
avg, IF

5.19
L-index

#	Paper	IF	Citations
96	Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 42, 1-19	7.1	0
95	Automated detection and segmentation of non-small cell lung cancer computed tomography images. <i>Nature Communications</i> , 2022 , 13,	17.4	5
94	Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations. <i>Oncologist</i> , 2021 , 26, e1347-e1358	5.7	13
93	Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study.. <i>Cancers</i> , 2021 , 13,	6.6	2
92	Life-prolonging treatment restrictions and outcomes in patients with cancer and COVID-19: an update from the Dutch Oncology COVID-19 Consortium. <i>European Journal of Cancer</i> , 2021 ,	7.5	2
91	Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non-small cell lung cancer treated with immunotherapy. <i>European Journal of Cancer</i> , 2021 , 145, 221-229	7.5	14
90	Radiation for Oligometastatic Lung Cancer in the Era of Immunotherapy: What Do We (Need to) Know?. <i>Cancers</i> , 2021 , 13,	6.6	2
89	Biomarkers of Radiotherapy-Induced Immunogenic Cell Death. <i>Cells</i> , 2021 , 10,	7.9	10
88	The prognostic value of weight and body composition changes in patients with non-small-cell lung cancer treated with nivolumab. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 , 12, 657-664	10.3	3
87	Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy. <i>Lung Cancer</i> , 2021 , 155, 163-169	5.9	5
86	Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands. <i>Lung Cancer</i> , 2021 , 155, 103-113	5.9	3
85	Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2868-2875	4.4	0
84	Immunotherapy in small cell lung cancer: one step at a time: a narrative review. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2970-2987	4.4	1
83	Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma-A Systematic Review. <i>Cancers</i> , 2021 , 13,	6.6	1
82	How to optimize the incorporation of immunotherapy in trials for oligometastatic non-small cell lung cancer: a narrative review. <i>Translational Lung Cancer Research</i> , 2021 , 10, 3486-3502	4.4	1
81	Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics. <i>European Journal of Cancer</i> , 2021 , 151, 211-220	7.5	6
80	Idiopathic pulmonary fibrosis: Current knowledge, future perspectives and its importance in radiation oncology. <i>Radiotherapy and Oncology</i> , 2021 , 155, 269-277	5.3	6

79	Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2021 , 22, 51-65	21.7	101
78	Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy. <i>Clinical Cancer Research</i> , 2021 , 27, 492-503	12.9	31
77	Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment. <i>International Journal of Cancer</i> , 2021 , 149, 1576-1584	7.5	3
76	Targeted therapies for unresectable stage III non-small cell lung cancer.. <i>Mediastinum</i> , 2021 , 5, 22	0.5	1
75	Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 166, 103460	7	2
74	Combination treatments with immunotherapy in brain metastases patients. <i>Future Oncology</i> , 2020 , 16, 1691-1705	3.6	1
73	Risk factors for neurocognitive decline in lung cancer patients treated with prophylactic cranial irradiation: A systematic review. <i>Cancer Treatment Reviews</i> , 2020 , 88, 102025	14.4	9
72	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. <i>BMC Cancer</i> , 2020 , 20, 557	4.8	19
71	Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept. <i>Frontiers in Medicine</i> , 2020 , 7, 90	4.9	20
70	Efficacy of Ibandronate Loading Dose on Rapid Pain Relief in Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: The NVALT-9 Trial. <i>Frontiers in Oncology</i> , 2020 , 10, 890	5.3	2
69	The Emerging Role of Radiomics in COPD and Lung Cancer. <i>Respiration</i> , 2020 , 99, 99-107	3.7	20
68	ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases. <i>European Oncology and Haematology</i> , 2020 , 16, 18	0.1	2
67	Central nervous system metastases and oligoprogression during treatment with tyrosine kinase inhibitors in oncogene-addicted non-small cell lung cancer: how to treat and when?. <i>Translational Lung Cancer Research</i> , 2020 , 9, 2599-2617	4.4	0
66	Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry. <i>Lung Cancer</i> , 2020 , 140, 107-112	5.9	17
65	Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 383-391	8.9	30
64	Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI). <i>Cancers</i> , 2020 , 12,	6.6	14
63	Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study. <i>BMJ Open</i> , 2020 , 10, e036492	3	3
62	EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins. <i>Cancer Treatment Reviews</i> , 2020 , 90, 102105	14.4	31

61	Differentiation of COVID-19 Pneumonitis and ICI Induced Pneumonitis. <i>Frontiers in Oncology</i> , 2020 , 10, 577696	5.3	8
60	Non-Radiation Based Early Pain Relief Treatment Options for Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: A Systematic Review. <i>Frontiers in Oncology</i> , 2020 , 10, 509297	5.3	0
59	Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study. <i>European Journal of Cancer</i> , 2020 , 141, 171-184	7.5	37
58	Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context. <i>OncoTargets and Therapy</i> , 2020 , 13, 6885-6896	4.4	1
57	Palliative Care for Cancer Patients During the COVID-19 Pandemic, With Special Focus on Lung Cancer. <i>Frontiers in Oncology</i> , 2020 , 10, 1405	5.3	7
56	Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey. <i>Lung Cancer</i> , 2019 , 136, 145-147	5.9	9
55	Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019 , 116, 182-189	7.5	23
54	Imaging of regional ventilation: Is CT ventilation imaging the answer? A systematic review of the validation data. <i>Radiotherapy and Oncology</i> , 2019 , 137, 175-185	5.3	10
53	Screening for brain metastases in patients with stage III non-small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study. <i>European Journal of Cancer</i> , 2019 , 115, 88-96	7.5	12
52	Immune checkpoint inhibitors in non-small-cell lung cancer: key to long-term survival?. <i>Lancet Respiratory Medicine</i> , 2019 , 7, 291-292	35.1	1
51	Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1244-1254	8.9	106
50	Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-Year results of a prospective study. <i>Radiotherapy and Oncology</i> , 2019 , 135, 141-146	5.3	12
49	Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 2053-2061	8.9	25
48	Prevention and Early Detection for NSCLC: Advances in Thoracic Oncology 2018. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1513-1527	8.9	52
47	Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1400-1407	8.9	16
46	Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 2109-2119	8.9	96
45	Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion. <i>European Journal of Cancer</i> , 2019 , 123, 28-35	7.5	6
44	EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease. <i>European Journal of Cancer</i> , 2019 , 122, 109-114	7.5	10

43	Circulating tumor DNA analysis (ctDNA) for genomic testing in NSCLC patients with isolated CNS progression.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2015-2015	2.2	
42	The electronic nose: emerging biomarkers in lung cancer diagnostics. <i>Breathe</i> , 2019 , 15, e135-e141	1.8	6
41	Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1701-1703	8.9	4
40	Prospects of targeted and immune therapies in SCLC. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 151-167	3.5	5
39	Responding to the challenges of international collaborations between the east and the west - report of the first JCOG-EORTC symposium and a perspective from young JCOG and EORTC investigators. <i>Japanese Journal of Clinical Oncology</i> , 2019 , 49, 96-99	2.8	2
38	Diversity of brain metastases screening and management in non-small cell lung cancer in Europe: Results of the European Organisation for Research and Treatment of Cancer Lung Cancer Group survey. <i>European Journal of Cancer</i> , 2018 , 93, 37-46	7.5	46
37	Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. <i>European Journal of Cancer</i> , 2018 , 91, 92-98	7.5	21
36	Invasive Aspergillosis Mimicking Metastatic Lung Cancer. <i>Frontiers in Oncology</i> , 2018 , 8, 188	5.3	9
35	Stereotactic Radiosurgery in the Management of Patients With Brain Metastases of Non-Small Cell Lung Cancer: Indications, Decision Tools and Future Directions. <i>Frontiers in Oncology</i> , 2018 , 8, 154	5.3	26
34	Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 124, 6-11	5.9	20
33	The Prevention of Brain Metastases in Non-Small Cell Lung Cancer by Prophylactic Cranial Irradiation. <i>Frontiers in Oncology</i> , 2018 , 8, 241	5.3	13
32	What you see is (not) what you get: tools for a non-radiologist to evaluate image quality in lung cancer. <i>Lung Cancer</i> , 2018 , 123, 112-115	5.9	1
31	Deleterious effect of baseline steroids on efficacy of PD-(L)1 blockade in patients with NSCLC.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9003-9003	2.2	12
30	Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9066-9066	2.2	
29	Assessment of clinical, radiological and radiomic predictive factors of bevacizumab efficacy in brain metastases radionecrosis treatment.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e14003-e14003	2.2	
28	Assessment of efficacy and safety of bevacizumab in the treatment of brain metastases radionecrosis: A retrospective cohort analysis.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e14014-e14014	2.2	
27	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2872-2878	2.2	477
26	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. <i>Translational Lung Cancer Research</i> , 2018 , 7, 647-660	4.4	50

25	Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO). <i>Annals of Oncology</i> , 2018 , 29, viii511	10.3	4
24	External validation of an NTCP model for acute esophageal toxicity in locally advanced NSCLC patients treated with intensity-modulated (chemo-)radiotherapy. <i>Radiotherapy and Oncology</i> , 2018 , 129, 249-256	5.3	5
23	Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450). <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1958-1961	8.9	43
22	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. <i>Cancer Treatment Reviews</i> , 2018 , 71, 47-58	14.4	28
21	Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer. <i>Lung Cancer</i> , 2018 , 121, 76-81	5.9	24
20	Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. <i>Cancer Treatment Reviews</i> , 2018 , 68, 69-79	14.4	36
19	Screening for Brain Metastases in Resectable Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017 , 12, e21	8.9	1
18	Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 4251-4258	12.9	48
17	Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors. <i>Oncologist</i> , 2017 , 22, 222-235	5.7	16
16	Heat shock protein antagonists in early stage clinical trials for NSCLC. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 541-550	5.9	42
15	Management of stage I and II nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	34
14	The Current Role of Whole Brain Radiation Therapy in Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2017 , 12, 1467-1477	8.9	16
13	Non-small cell lung cancer with a single metastasis, the new stage M1b; does the site matter?. <i>Cancer Treatment and Research Communications</i> , 2017 , 13, 1-2	2	
12	Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 155-73	8.9	30
11	Proposals for the M-descriptors of the Eight TNM Classification for Non-Small Cell Lung Cancer: Are More Data Needed?. <i>Journal of Thoracic Oncology</i> , 2016 , 11, e42-3	8.9	2
10	Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?. <i>Lung Cancer</i> , 2016 , 101, 68-75	5.9	7
9	Stage III Non-Small Cell Lung Cancer in the elderly: Patient characteristics predictive for tolerance and survival of chemoradiation in daily clinical practice. <i>Radiotherapy and Oncology</i> , 2016 , 121, 26-31	5.3	32
8	Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based study. <i>European Journal of Cancer</i> , 2015 , 51, 2534-44	7.5	37

7	Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2015 , 90, 249-54	5.9	18
6	An Uncommon Presentation of Brain Metastases in a Lung Cancer Patient. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1655-6	8.9	1
5	Safety of cranial radiotherapy concurrent with tyrosine kinase inhibitors in non-small cell lung cancer patients: A systematic review. <i>Cancer Treatment Reviews</i> , 2015 , 41, 634-45	14.4	29
4	Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: Impact of a new Dutch guideline on brain metastases. <i>Acta Oncologica</i> , 2014 , 53, 945-51	3.2	11
3	EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?. <i>Lung Cancer</i> , 2014 , 84, 86-91	5.9	81
2	Retrospective analysis of type of KRAS mutation (mut) and response to first-line platinum-based chemotherapy (PC) in non-small cell lung cancer (NSCLC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8061-8061	2.2	1
1	Screening for brain metastases in patients with stage III non-small cell lung cancer: Is there additive value of magnetic resonance imaging above a contrast-enhanced computed tomography of the brain?. <i>Lung Cancer</i> , 2013 , 80, 293-7	5.9	14